Influence of inoculum size of Staphylococcus aureus and Pseudomonas aeruginosa on in vitro activities and in vivo efficacy of fluoroquinolones and carbapenems

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 1, 2005, Pages 91-96

  Mizunaga, Shingo ^a   Kamiyama, Tomoko ^a   Fukuda, Yoshiko ^a   Takahata, Masahiro ^a   Mitsuyama, Junichi ^a  

^a TOYAMA CHEMICAL CO LTD   (Japan)

Author keywords

Bactericidal activity; Post antibiotic effect; Protective effect

Indexed keywords

CARBAPENEM DERIVATIVE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; IMIPENEM; MEROPENEM; PANIPENEM; PANIPENEM PLUS BETAMIPRON; PAZUFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; OXAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG EFFICACY; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; POSTANTIBIOTIC EFFECT; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; ANIMAL; DRUG EFFECT; GRAM NEGATIVE INFECTION; INSTITUTE FOR CANCER RESEARCH MOUSE; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; STAPHYLOCOCCUS INFECTION;

ANIMALS; CARBAPENEMS; CIPROFLOXACIN; FLUOROQUINOLONES; MALE; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; OXAZINES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 24044501305     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki163     Document Type: Article

References (24)

1. Alvarez-Lerma, F., Pavesi, M., Calizay, M. [i#et al.#1i] (2001). Risk and prognostic factors of [i#Pseudomonas aeruginosa#1i] bacteremia in critically ill patients. [i#Medicina Clinica#1i] [b#117#1b], 721-6.
2. Kowalik, M., Ellert-Zygadlowska, J., Smiatacz, T. [i#et al.#1i] (2001). [i#Staphylococcus aureus#1i] sepsis-still life threatening disease. [i#Polski Merkuriusz Lekarski#1i] [b#11#1b], 352-6.
3. Bradley, J.S., Garau, J., Lode, H. [i#et al.#1i] (1999). Carbapenems in clinical practice: A guide to their use in serious infection. [i#Int J Antimicrob Agents#1i] [b#11#1b], 93-100.
4. Krumpe, P. E., Cohn, S., Garreltes, J. [i#et al.#1i] (1999). Intravenous and oral mono- or combination-therapy in the treatment of severe infections: Ciprofloxacin versus standard antibiotic therapy. Ciprofloxacin Study Group. [i#J Antimicrob Chemother#1i] [b#43#1b], [i#Suppl. A#1i], 117-28.
5. File, T. M. Jr., Segreti, J., Dunbar, L. [i#et al.#1i] (1997). A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. [i#Antimicrob Agents Chemother#1i] [b#41#1b], 1965-72.
6. Bolmstrom, A., Esberg, K., Wiman, A. [i#et al.#1i] (1996). Effects of CO2 incubation on MICs of macrolides? [i#In Programs and Abstracts of the Thirty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996#1i], Poster D38, p. 67. American Society for Microbiology, Washington, DC, USA.
7. König, C., Simmen, H. P. & Blaser, J. (1993). Effect of pathological changes of pH, and pCO2 on the activity of antimicrobial agents [i#in vitro. Eur J Clin Microbiol Infecti Dis#1i] [b#12#1b], 519-26.
8. Malanoski, G. J., Eliopoulos, G. M., Ferraro, M. J. [i#et al.#1i] (1993). Effect of pH variation on the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and temafloxacin. [i#Eur J Clin Microbiol Infect Dis#1i] [b#12#1b], 131-3.
9. Johnson, C. C., Livornese, L., Gold, M. J. [i#et al.#1i] (1995). Activity of cefepime against ceftazidime-resistant gram-negative bacilli using low and high inocula. [i#J Antimicrob Chemother#1i] [b#35#1b], 765-73.
10. Fass, R. J. (1983). In vitro activity of ciprofloxacin (Bay o 9867). [i#Antimicrob Agents Chemother#1i] [b#24#1b], 568-74.
11. Stearne, L. E., Kooi, C., Goessens, W. H. [i#et al.#1i] (2001). In vitro activity of trovafloxacin against [i#Bacteroides fragilis#1i] in mixed culture with either [i#Escherichia coli#1i] or a vancomycin-resistant strain of [i#Enterococcus faecium#1i] determined by an anaerobic time-kill technique. [i#Antimicrob Agents Chemother#1i] [b#45#1b], 243-51.
12. König, C., Simmen, H. P. & Blaser, J. (1998). Bacterial concentrations in pus and infected peritoneal fluid-implications for bactericidal activity of antibiotics. [i#J Antimicrob Chemother#1i] [b#42#1b] 227-32.
13. Soriano, F., Garcia-Corbeira, P., Ponte, C. [i#et al.#1i] (1996). Correlation of pharmacodynamic parameters of five beta-lactam antibiotics with therapeutic efficacies in an animal model. [i#Antimicrob Agents Chemother#1i] [b#40#1b], 2686-90.
14. Chuang, Y. C., Ko, W.C., Wang, S. T. [i#et al.#1i] (1998). Minocycline and cefotaxime in the treatment of experimental murine [i#Vibrio vulnificus#1i] infection. [i#Antimicrob Agents Chemother#1i] [b#42#1b], 1319-22.
15. Japan Society of Chemotherapy (1981). Method for the determination of minimum inhibitory concentration (MIC) of aerobic bacteria by agar dilution method. [i#Chemotherapy (Tokyo)#1i] [b#29#1b], 76-9.
16. Brook, I. (1990). Inoculum effect. [i#Rev Infect Dis#1i] [b#11#1b], 361-8.
17. Soriano, F. (1992). Optimal dosage of beta-lactam antibiotics: Time above the MIC and inoculum effect. [i#J Antimicrob Chemother#1i] [b#30#1b] 566-9.
18. Tsuji, A., Kaneko, Y., Yamaguchi, K. [i#et al.#1i] (1994). Correlation between the [i#in vitro#1i] and [i#in vivo#1i] effects of fourteen beta-lactam compounds in mice with systemic infection. [i#Chemotherapy (Basel)#1i] [b#5#1b], 324-32.
19. Craig, W. A. & Gudmundsson, S. (1991). The postantibiotic effect. In [i#Antibiotics in Laboratory Medicine#1i], 2nd edn (Lorian, V., Ed.), pp. 515-36. Williams & Wilkins, Baltimore, MD, USA.
20. Gerber, A. U., Brugger, H. P., Feller, C. [i#et al.#1i] (1986). Antibiotic therapy of infections due to [i#Pseudomonas aeruginosa#1i] in normal and granulocytopenic mice: Comparison of murine and human pharmacokinetics. [i#J Infect Dis#1i] [b#153#1b], 90-7
21. Bustamante, C. I., Drusano, G. L., Tatem, B. A. [i#et al.#1i] (1984). Postantibiotic effect of imipenem on [i#Pseudomonas aeruginosa. Antimicrob Agents Chemother#1i] [b#26#1b], 678-82.
22. Nadler, H. L., Pitkin, D. H. & Sheikh, W. (1989). The postantibiotic effect of meropenem and imipenem on selected bacteria. [i#J Antimicrob Chemother#1i] [b#24#1b], [i#Suppl. A#1i], 225-31.
23. Kunin, C. M. (1981). Dosage schedules of antimicrobial agents: A historical review. [i#Rev Infect Dis#1i] [b#3#1b], 4-11.
24. Vogelman, B. S. & Craig, W. A. (1985). Postantibiotic effects. [i#J Antimicrob Chemother#1i] [b#15#1b], [i#Suppl. A#1i], 37-46.